Thermo Fisher Scientific to acquire Phadia

Pen

Thermo Fisher Scientific Inc. has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven for €2.47bn (approx. $3.5bn) in cash.

Thermo Fisher Scientific Inc. has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics,from European private equity firm Cinven for €2.47bn (approx. $3.5bn) in cash.

You must be a subsciber to read this content

If you already subscribe, please sign-in now

Subscribe to Gas World

 

Get instant access to must-read content from top industry writers!

To access hundreds of features, subscribe today! Discover the in-depth content our subscribers receive every month by reading this week’s free feature. Join gasworld and become a subscriber to access all of our content online from just $270.